Pyritinol has been studied as a cognitive-enhancing drug in children with learning difficulties, older adults with substantial cognitive impairment, and healthy young volunteers. The results differ considerably depending on the population and the cognitive function being measured.
Across these controlled studies, pyritinol did not produce a consistent improvement in memory. Some trials did, however, find effects on attention, vigilance, reaction time, or broader measures of cognitive impairment.
Key Takeaways
- Pyritinol did not significantly improve any of 22 cognitive measures in a six-month study of children with learning difficulties.
- Older adults with moderate to relatively severe organic mental disorders improved significantly on two clinical and cognitive measures after 12 weeks of pyritinol treatment.
- Healthy young adults showed faster reaction-related performance and increased critical flicker fusion thresholds, but no significant improvement in short-term memory.
- The three studies do not establish pyritinol as a general-purpose memory enhancer, and differences in population, dose, duration, and testing make direct comparisons difficult.
What Is Pyritinol?
Pyritinol, historically also called pyrithioxine, is a synthetic compound structurally related to pyridoxine, or vitamin B6. Its pharmacological effects were studied separately from the nutritional actions normally associated with vitamin B6.
Older research cited in the clinical literature associated pyritinol with increased cerebral glucose utilisation, changes in cerebral blood flow, alterations in EEG activity related to vigilance, and increased cortical acetylcholine release. These findings led researchers to investigate whether pyritinol could improve memory, attention, and other cognitive functions.
Does Pyritinol Improve Cognition in Children With Learning Difficulties?
Wälti and colleagues studied 67 children aged 11 to 16 who attended slow-learner classes in Bern, Switzerland. Thirty-five received pyritinol and 32 received placebo for six months under double-blind conditions. The daily pyritinol dose was 300 mg.
The researchers assessed 22 measures covering visual perception, short-range and sustained attention, verbal performance, academic skills, and IQ. Tests included digit recall, story retelling, arithmetic, dictation, and several visual and attentional tasks.
None of the 22 measures showed a statistically significant average advantage for pyritinol over placebo. An analysis that considered the cognitive measures together also failed to distinguish the two treatment groups.
Four measures showed significantly greater variability in the pyritinol group. The researchers considered whether this could mean that some children improved while others performed worse, causing the average effect to disappear.
They then tested whether age, body weight, IQ, reaction speed, short-term memory, or other characteristics could identify likely responders. None of the 15 subgroup criteria produced a reliable treatment effect.
The study therefore found no evidence that pyritinol generally improved cognitive performance in children with learning difficulties. It also failed to identify a subgroup that could be predicted to benefit.
Does Pyritinol Improve Cognition in Older Adults?
Herrmann, Kern, and Röhmel studied 120 geriatric patients with what the authors described as moderate to relatively severe organic mental disorders or chronic brain syndrome. These historical diagnostic terms encompassed disturbances in areas such as memory, concentration, thinking, motivation, affect, and psychomotor function.
After a two-week placebo washout period, patients entered 12 weeks of randomised, double-blind treatment. Those assigned to pyritinol received 200 mg three times daily, for a total of 600 mg per day.
Thirteen participants were excluded from the analysis, leaving 107 patients: 54 receiving pyritinol and 53 receiving placebo.
The researchers used four primary measures:
- the Sandoz Clinical Assessment Geriatric Scale, or SCAG
- the physician’s Global Impression
- the Syndrom-Kurztest, or SKT
- the ZVT-G test of information-processing speed
The SCAG total score improved significantly more with pyritinol than placebo. Average scores improved by 15.2% in the pyritinol group and 9.4% in the placebo group.
The SKT, which measured disturbances of attention and memory, also significantly favoured pyritinol. Scores improved by 24.7% with pyritinol compared with 12.2% with placebo, and the difference remained significant after adjustment for multiple comparisons.
The physician’s Global Impression and ZVT-G did not significantly distinguish pyritinol from placebo.
A descriptive analysis of the SKT separated concentration from recent memory. Recent memory favoured pyritinol, while the concentration component did not reach statistical significance.
This trial provides the clearest evidence among the three studies that pyritinol can affect clinically relevant cognitive deficits, although the benefit did not extend across every measure used.
Does Pyritinol Affect Cognition in Healthy Adults?
Hindmarch, Coleston, and Kerr tested pyritinol in 12 healthy men aged 19 to 26 using a randomised, double-blind crossover design. Each participant received placebo, 600 mg of pyritinol, and 1,200 mg of pyritinol during separate three-day treatment periods.
The researchers measured critical flicker fusion threshold, reaction time, short-term memory, and subjective drug effects.
Critical flicker fusion threshold increased significantly under pyritinol. The authors used this measure as an indicator of central nervous system activity and information-processing capacity, with the 1,200 mg condition producing the clearest increases at several testing points.
Total reaction time was also significantly faster with pyritinol. Further analysis showed that the effect came mainly from recognition reaction time, the interval needed to identify a stimulus and initiate a response. Motor reaction time itself did not change significantly.
Neither of the two short-term memory tests showed a significant improvement. One involved recognising digits from memorised sequences, while the other tested recognition of previously presented words.
The authors noted that the memory tasks may have been too easy for the university students participating in the study, with baseline performance already close to the maximum possible score. The experiment nevertheless demonstrated measurable effects on vigilance and reaction-related processing without demonstrating better short-term memory.
Does Pyritinol Improve Memory?
The memory findings are inconsistent.
The six-month children’s trial found no significant advantage across a broad cognitive battery that included several memory-related tasks. Healthy volunteers also showed no significant improvement on either short-term memory test.
The geriatric trial produced a different result. Pyritinol significantly improved the SKT total score, which incorporated attention and memory, and the descriptive analysis of recent memory also favoured pyritinol.
The available studies therefore provide some evidence of memory-related benefit in people with substantial cognitive impairment, but they do not show that pyritinol reliably improves memory in healthy people or in children with learning difficulties.
Does Existing Cognitive Impairment Affect the Response?
The strongest positive findings occurred in the geriatric trial, where participants already had moderate to relatively severe cognitive and functional deficits. The healthy-volunteer study detected narrower effects on vigilance and reaction speed, while the children’s trial found no average cognitive benefit.
These studies cannot determine whether baseline cognitive impairment itself explains that pattern. They differed substantially in age, clinical status, dosage, treatment duration, and the tests used to measure cognition.
The healthy volunteers received pyritinol for three days, compared with 12 weeks in the geriatric trial and six months in the children’s study. A study comparing impaired and unimpaired participants under the same protocol would be needed to determine whether cognitive impairment predicts a stronger response.
How Strong Is the Evidence?
These trials were published between 1975 and 1991, so the evidence examined here comes from an older period of psychopharmacology.
The healthy-volunteer study included only 12 participants and lasted three days. Its crossover design allowed each participant to receive both pyritinol and placebo, but the small sample limits how confidently its results can be generalised.
The geriatric study was larger and used randomisation, double blinding, and placebo control over 12 weeks. It produced significant findings on two of its four primary outcome measures. Its diagnostic terminology and assessment framework, however, reflect geriatric psychiatry of the 1980s.
The children’s trial lasted six months and examined 22 cognitive measures, making its absence of an average treatment effect particularly relevant to claims of broad cognitive enhancement.
Differences between the three studies prevent a simple pooled conclusion. They are more useful for showing which cognitive domains produced measurable effects and which did not.
Bottom Line
Pyritinol has produced measurable cognitive effects in controlled human studies, but it has not consistently improved memory or overall cognitive performance. The most convincing positive results came from older adults with substantial cognitive impairment, while healthy volunteers showed effects on vigilance and reaction-related performance without better short-term memory.
The evidence therefore supports a narrower interpretation of pyritinol’s cognitive effects than the idea of a general memory enhancer.
References
Hindmarch, I., Coleston, D. M., & Kerr, J. S. (1990–1991). Psychopharmacological effects of pyritinol in normal volunteers. Neuropsychobiology, 24(3), 159–164. https://doi.org/10.1159/000119478
Herrmann, W. M., Kern, U., & Röhmel, J. (1986). On the effects of pyritinol on functional deficits of patients with organic mental disorders. Pharmacopsychiatry, 19(5), 378–385. https://doi.org/10.1055/s-2007-1017274
Wälti, U., Kuenzler, M., Schild, J., Vassella, F., Pavlincova, E., Bircher, J., & Herschkowitz, N. (1975). Pyritinol hydrochloride and cognitive functions: Influence on children in slow learner classes. Pediatric Research, 9(9), 717–721. https://doi.org/10.1203/00006450-197509000-00006
Leave a Reply